Revenue -12.6% YoY, PAT -46.7%; long-term bets positioned but near-term opaque

H1 FY27 ₹1107.2 Cr vs H1 FY26 ₹816.7 Cr; +35.6% YoY, but Q2 alone -12.6%

Q2 revenue -29.9% QoQ, PAT down 65.0% QoQ; major quarter-on-quarter deterioration

No quantified guidance provided; prior call said ~20% FY27-28 growth; now refuses specificity

Management states this; no supporting numbers; Q4 normalization is a 6-month forward claim

Q2 CMS ₹214 Cr (per management); commercial NCEs contributing but uneven

H1 FY27 ₹1107 Cr (+35.6% vs H1 FY26) masks Q2 weakness; Q2 FY27 ₹450 Cr (-12.6% vs Q2 FY26). Sequential Q1→Q2 decline -29.9%. Prior call expected FY27-28 ~20% growth; path is now off track.

No normalized EBITDA margin guidance restated. Prior call mentioned 'normalized ~25%' (vs 35.5% boosted by FX/mix). Q2 delivered 22.9%, below even the normalized target.

Geopolitical headwinds unexpected; management now says normalization by Q4, but Q2 shows acute weakness. Not in prior commentary.

Facility now operational (Module 1); Kakinada land acquired (134 acres). This is new confidence-building infrastructure, not in prior call detail.

We enter MSA for PPQ validation, then commercial supply. If idle post-setup, that cost is borne by Neuland; we accept that risk for the long-term diversification value. Kakinada is part of that long-term expansion vision.

Theoretical question. We believe sustained demand for peptide API and continue investment. If impact on CMS, we modulate move to Kakinada. But we don't give color on individual molecule level.

No new launch in last 2-3 quarters. Orders are lumpy; depends on customer timing. Last launch ~1 year ago. Commercial NCEs will continue to drive, but shipments are uneven. Not all linked to volumes.

Customers had challenges manufacturing product; impacts topline and bottom-line. We expect things to normalize by Q4 based on customer feedback.

It is difficult. I do not think we are precise enough to go into more clarity there. 2027 will grow and 2028 will grow, but we do not want to share numbers.

6 to 9 months for PPQ, then 6 months more for MSA pivot to commercial. So 1.5-2 years before real commercial revenue flows.

AI will increase project volume, but clinical trial bottleneck remains (human limitation). We see AI as a tailwind for the number of projects in our funnel, and we can design processes around it. Not a direct threat to CDMO work; mostly at IND stage today.

Our business follows development and commercial requirements. Molecules are not produced continuously; shipments vary by customer timing. A handful of molecules drive commercial revenue, so uneven flow is permanent. Over 15 years in CDMO, lumpiness is part of the scale-up model.

Peptide synthesis is considered irreversible. Impurities are hard to remove; you have to junk the batch. Precision in downstream is critical. We've done process development at small scale; now scaling to 500L reactor. We're building in quality and talent alongside scale.

Center will focus on peptides and small molecules first. Not oligos or ADCs immediately. Goal is process development and integrated capability across peptide APIs and small molecules to support customer needs.

Approximately ₹1700 Crores over next 3 years, broad number. Kakinada will bring certain factors; Module 2 capex not crystallized yet. ~₹250 Cr spent in Module 1. We'll finalize as projects move forward.

Number of new molecules is increasing faster than size of existing ones. This is confirmed. We have become more selective as we scale up; pedrigree of customer conversations has changed — bigger pharma involvement now.

There will be some testing and correction. However, not all peptides are multi-metric ton; many are 100g, some 10g, 1kg, etc. Our goal is to be a dominant player in peptide APIs for therapeutics. In India, talent constraint for CDMO peptides exists, not overcapacity. Globally, there may be excess in China.

No numeric target. Prior call said ~20% FY27-28 growth; now management refuses to repeat. Vague reaffirmation without numbers.

Prior call: 'normalized EBITDA ~25%'. Q2 delivered 22.9%. No guidance on path back to 25%.

Broad guidance; ~₹567 Cr/year average. Module 2 and Kakinada phasing not yet detailed; will refine in next 3-6 months.

Top 5 customers contribute 68% of revenues. Single customer loss could reduce PAT >20% given operating leverage. Management has not diversified enough despite 15 years in business.

EBITDA margin 22.9% vs prior-year 30.4% (740 bps miss). Driven by input inflation, freight costs, FX headwinds, and uneven shipment absorption. No credible recovery timeline stated.

Peptide facility operational but revenue recognition 1-1.5 years away (MSA validation, PPQ completion, then supply). If projects slip or are cancelled, Neuland absorbs facility idle cost. Module 2 capex not yet finalized.

GDS business (generic drug services) saw unexpected customer manufacturing challenges due to geopolitical tensions. Resulted in Q2 revenue/margin miss. Recovery by Q4 FY27 not guaranteed.

WC cycle expanded from 84 days to 104 days (+20 days), indicating either inventory buildup for anticipated orders or slower receivables collection. Ties up cash and signals execution challenge.